IP Library Granted Patent US 10,216,897
Granted Patent B2
US 10,216,897 · App. 15/004,742 · Granted Feb 26, 2019

Construction of diverse synthetic peptide and polypeptide libraries

Inventors: Lawrence Horowitz (Atherton, CA); Ramesh Bhatt (Belmont, CA); Aaron L. Kurtzman (San Carlos, CA)
Assignee: I2 PHARMACEUTICALS, INC.
G06F19/22C07K16/005C07K16/22C07K16/241C07K16/249C07K16/44C07K16/461C12N15/1058C40B50/02G06F19/28C07K2317/21C07K2317/56C07K2317/565C07K2317/567C07K2317/622C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,216,897
App. No.
15/004,742
Granted
Feb 26, 2019
Kind
B2
Abstract

The present invention concerns the design and construction of diverse peptide and polypeptide libraries. In particular, the invention concerns methods of analytical database design for creating datasets using multiple relevant parameters as filters, and methods for generating sequence diversity by directed multisyntheses oligonucleotide synthesis. The present methods enable the reduction of large complex annotated databases to simpler datasets of related sequences, based upon relevant single or multiple key parameters that can be individually directly defined. The methods further enable the creation of diverse libraries based on this approach, using multisynthetic collections of discrete and degenerate oligonucleotides to capture the diverse collection of sequences, or portions thereof.

Claims (26)

1. A method of making a library of antibody heavy or light chains, comprising the steps of

(a) aligning a plurality of antibody heavy or light chain sequences comprising one or more CDR sequence motifs;

(b) creating a first dataset by applying a predetermined combination of two or more filters based on parameters of said antibody heavy or light chain sequences;

(c) analyzing said first dataset for positional amino acid usage frequency within at least one of said CDR sequence motifs;

(d) creating a second dataset characterized by a minimum threshold amino acid usage frequency at one or more amino acid positions within said CDR sequence motif; and

(e) synthesizing an antibody heavy or light chain library designed with the aid of the first and second datasets identified, by generating a discrete number of defined or degenerate oligonucleotides such that only defined amino acids are generated.

2. The method of claim 1 wherein said sequence motif is a CDR sequence selected from the group consisting of CDR1, CDR2 and CDR3 sequences.

3. The method of claim 1 wherein in step (b) said predetermined combination of filters is selected from the group consisting of: (1) the isotype of said antibody heavy or light chain; (2) the length of one or more CDR1, CDR2 and CDR3 sequences; (3) the presence of one or more predetermined amino acid residues at one or more predetermined positions within one or more CDR1, CDR2 and CDR3 sequences; (4) type of framework; (5) antigen to which said antibody binds; (6) affinity of said antibody; and (7) positional amino acid residues outside said CDR sequences.

4. The method of claim 3 wherein at least one of the antibody heavy and/or light chain CDR1, CDR2 and CDR3 sequences is size matched.

5. The method of claim 4 wherein an additional filter is the isotype of said antibody heavy and/or light chain sequences.

6. The method of claim 1 wherein said positional amino acid usage frequency is between at least about 3% and at least about 15%.

7. The method of claim 1 wherein the same positional amino acid usage frequency characterizes each amino acid within said CDR sequence.

8. The method of claim 1 wherein the positional amino acid usage frequencies differ at least two amino acid residues within said CDR sequence.

9. The method of claim 3 wherein said predetermined combination of filters includes the type of framework.

10. The method of claim 1 wherein both antibody heavy and light chain sequences are analyzed, and the antibody heavy chain sequences are paired to predetermined antibody light chain characteristics, or the antibody light chain sequences are paired to predetermined antibody heavy chain characteristics.

11. The method of claim 1 wherein said related antibody sequences are from at least one functional antibody.

12. The method of claim 1 wherein one of said filters applied in step (b) is the germline sequence most similar to the framework sequence of the heavy and/or light chain of said functional antibody.

13. The method of claim 1 wherein said functional antibody binds to a polypeptide selected from the group consisting of cell surface and soluble receptors, cytokines, growth factors, enzymes; proteases; and hormones.

14. The method of claim 1 wherein in step (d) a minimum threshold amino acid usage frequency is assigned to at least the majority of amino acid positions within said shared sequence motif.

15. The method of claim 1 wherein said minimum threshold amino acid usage frequency is set to provide a minimum sum amino acid usage for the majority of amino acid positions within said shared sequence motif.

16. The method of claim 1 wherein said minimum threshold amino acid usage frequency is set to provide a minimum sum amino acid usage for all amino acid positions within said shared sequence motif.

17. The method of claim 15 wherein said minimum sum amino acid usage is between at least about 60% and at least about 90%.

18. The method of claim 1 wherein said library is expressed using a prokaryotic or eukaryotic expression system.

19. The method of claim 1 wherein said library is expressed and displayed using a phagemid display, mRNA display, microbial cell display, mammalian cell display, microbead display technique, antibody array, or display based on protein-DNA linkage.

20. The method of claim 1 wherein said library is screened for one or more chemical and/or biological properties of its members.

21. The method of claim 20 wherein said biological property is selected from the group consisting of half-life, potency, efficacy, binding affinity, and immunogenicity.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2025
From: REVOPSIS THERAPEUTICS, INC.
To: REVOPSIS HOLDINGS, LLC
Reel/Frame 072793/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2024
From: BIOASSETS, LLC
To: REVOPSIS THERAPEUTICS, INC.
Reel/Frame 066055/0107 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2023
From: I2 PHARMACEUTICALS, INC.
To: BIOASSETS, LLC
Reel/Frame 064003/0129 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: HOROWITZ, LAWRENCE; BHATT, RAMESH; KURTZMAN, AARON L.
To: SEA LANE BIOTECHNOLOGIES, LLC.
Reel/Frame 041128/0321 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: SEA LANE BIOTECHNOLOGIES, LLC.
To: ALTUS BIOPHARMA INC.
Reel/Frame 041154/0070 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2016
From: ALTUS BIOPHARMA INC.
To: I2 PHARMACEUTICALS, INC.
Reel/Frame 041154/0613 →
Continuity (4)
Continuation 13374203 · Dec 14, 2011
Division 11864525 · Sep 28, 2007
Provisional Application 60849035 · Oct 2, 2006
Related Publication 20160132639A1 · May 12, 2016